4-(dimethylamino)-1,1-dimethoxy-but-3-en-2-one | 67751-23-9

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(dimethylamino)-1,1-dimethoxy-but-3-en-2-one
• 英文别名: 1,1-dimethoxy-4-dimethylamino-but-3-ene-2-one；4-(dimethylamino)-1,1-dimethoxy-3-buten-2-one；4-(dimethylamino)-1,1-dimethoxybut-3-en-2-one；1,1-dimethoxy-4-dimethylaminobut-3-en-2-one；4-dimethylamino-1,1-dimethoxybut-3-en-2-one；(4,4-dimethoxy-3-oxobut-1-en-1-yl)dimethylamine
• CAS: 67751-23-9
• 化学式: C₈H₁₅NO₃
• 分子量: 173.212
• InChiKey: DFZIBCAWOSFLFR-UHFFFAOYSA-N

物化性质

• 沸点：
  110 °C
• 密度：
  1.008g/ml

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2922509090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-(dimethylamino)-1,1-dimethoxy-but-3-en-2-one 在 一水合肼 作用下， 以 水 为溶剂， 反应 24.0h， 生成 吡唑-3-甲醛二甲基缩醛
  参考文献：
  名称：

  Synthesis and biological activities of meribendan and related heterocyclic benzimidazolo-pyridazinones

  摘要：

  The synthesis of new heterocyclic benzimidazolo-pyridazinones is described. The new compounds were evaluated as inotropic agents with 'calcium-sensitizing' effects. 5-Methyl-6-[2-(3-pyrazolyl)-5-benzimidazolyl]-2,3,4,5-tetrahydro-pyridazin-3-one hydrochloride (meribendan) turned out to be the most interesting compound and was chosen for development as a positive inotrope.

  DOI：

  10.1016/0223-5234(93)90005-y
• 作为产物：
  描述：

  1,1-二甲氧基丙酮 、 N,N-二甲基甲酰胺二甲基缩醛 以99%的产率得到4-(dimethylamino)-1,1-dimethoxy-but-3-en-2-one
  参考文献：
  名称：

  反式二取代吡唑基环丙烷结构单元的合成

  摘要：

  摘要从容易获得的吡唑甲醛开始描述了反式-双取代的吡唑基环丙烷结构单元（即羧酸和胺）的非对映选择性合成。合成的关键步骤是相应的α，β-不饱和Weinreb酰胺的Corey-Chaikowsky环丙烷化。标题化合物分四步或六步制备，总产率分别为32-60％和17-40％（最大50 g）。获得的构建块是设计类似铅的图书馆的良好起点；它们本身可以被认为是CNS活性药物tranylcyclopropamine的等排类似物。 图形概要

  DOI：

  10.1007/s00706-016-1726-6

文献信息

• Method for the Production of N-Substituted (3-Dihalomethyl-1-Methyl-Pyrazole-4-yl) Carboxamides
  申请人：Zierke Thomas

  公开号：US20100174094A1

  公开（公告）日：2010-07-08

  The present invention relates to a process for preparing N-substituted (3-dihalomethylpyrazol-4-yl)carboxamides of the formula (I) in which R 1 is optionally substituted phenyl or C 3 -C 7 -cycloalkyl, R 1a is hydrogen or fluorine, or R 1a together with R 1 is optionally substituted C 3 -C 5 -alkanediyl or C 5 -C 7 -cycloalkanediyl, R 2 is C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl or C 1 -C 4 -alkoxy-C 1 -C 2 -alkyl, X is F or Cl and n is 0, 1, 2 or 3; which comprises A) providing a compound of the formula (II) in which X is F or Cl, Y is Cl or Br and R 2 has one of the meanings given above and B) reacting a compound of the formula (II) with carbon monoxide and a compound of the formula (III) in which R 1 , R 1a and n have one of the meanings given above; in the presence of a palladium catalyst; to intermediates used for the preparation according to the process according to the invention, and also to processes for their preparation.

  本发明涉及一种制备式(I)的N-取代(3-二卤甲基吡唑-4-基)羧酰胺的方法 其中R1是可选的取代苯基或C3-C7环烷基，R1a是氢或氟，或者R1a与R1一起是可选的取代C3-C5-烷二基或C5-C7-环烷二基，R2是C1-C6-烷基，C2-C6-烯基，C2-C6-炔基或C1-C4-烷氧基-C1-C2-烷基，X是F或Cl，n为0、1、2或3；包括 A)提供式(II)的化合物 其中X是F或Cl，Y是Cl或Br，R2具有上述给定的含义之一 B)将式(II)的化合物与一氧化碳和式(III)的化合物反应 其中R1、R1a和n具有上述给定的含义之一；在钯催化剂的存在下； 用于根据本发明的方法制备的中间体，以及用于它们的制备的方法。
• [5,6]HETEROCYCLIC COMPOUND
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2565185A1

  公开（公告）日：2013-03-06

  Abstract: An object of the present invention is to provide a novel low molecular weight compound exhibiting an osteogenesis-promoting action. This object is achieved by a compound having the general formula (I) or a pharmacologically acceptable salt thereof. In the general formula (I), R1 and R2 represent hydrogen atoms, and the like; R3 represents a hydrogen atom, and the like; X, Y, and Z represent nitrogen atoms, and the like; A represents a phenylene group, and the like; n represents 1 or 2, and the like; and V and W represent oxygen atoms, and the like.

  摘要：本发明的目的是提供一种表现出促进骨生成作用的新型低分子量化合物。该目的通过具有通式（I）或其药理学可接受的盐的化合物实现。在通式（I）中，R1和R2代表氢原子等；R3代表氢原子等；X、Y和Z代表氮原子等；A代表苯基等；n代表1或2等；V和W代表氧原子等。
• [EN] MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE MCL-1 MACROCYCLIQUE ET PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2019035927A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y的化合物，这些化合物的任何值均在规范中定义，并且其药学上可接受的盐，可用作治疗疾病和病况，包括癌症的药物。还提供了包含Formula (I)中化合物的药物组合物。
• [EN] PYRIMIDINE DERIVATIVES POSSESSING CELL-CYCLE INHIBITORY ACTIVITY<br/>[FR] DERIVES DE PYRIMIDINE POSSEDANT UNE ACTIVITE INHIBITRICE SUR LE CYCLE CELLULAIRE
  申请人：ASTRAZENECA AB

  公开号：WO2004101564A1

  公开（公告）日：2004-11-25

  Compounds of the formula (I), and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti cell proliferation) effect in a warm blooded animal, such as man.

  该公式（I）的化合物，以及其药用可接受的盐和体内可水解的酯已被描述。还描述了它们的制备过程以及它们作为药物的用途，特别是作为在温血动物（如人类）中产生细胞周期抑制（抗细胞增殖）效果的药物。
• [EN] DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS<br/>[FR] INHIBITEURS DE DIACYLGLYCÉROL ACYLTRANSFÉRASE 2
  申请人：PFIZER

  公开号：WO2013150416A1

  公开（公告）日：2013-10-10

  Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H- imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

  这里描述了抑制二酰基甘油酰基转移酶2（DGAT2）活性的嘌呤衍生物，即式I的3H-咪唑并[4,5-b]嘧啶和1H-咪唑并[4,5-d]吡嗪，以及它们在治疗相关动物疾病中的用途。